Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.68 (tissue plasminogen activator)
 11,311 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Studies in the past 10 years have shown that there are two different, but related pathways for the acceleration of tissue-type plasminogen activator (t-PA) catalysis: (1) fibrin-dependent enhancement of t-PA amidolytic activity by fibrin binding; (2) fibrin-mediated stimulation of plasminogen activation by t-PA via the formation of a ternary complex of fibrin, t-PA and plasminogen. The common characteristic of both phenomena is the affinity of t-PA for fibrin, which is realized by the same enzyme binding site. However, a comparison of the kinetic data, the participating fibrin structures and the differences between single-chain and two-chain t-PA (sct-PA and tct-PA, respectively) shows that both phenomena have different causes. Fibrin-mediated stimulation of plasminogen activation involves both sct-PA and tct-PA and different fibrinogen derivatives such as fibrin, fibrinogen cyanogen bromide fragment FCB-2, fibrin alpha-chain and poly-lysine. This mechanism is described by a marked apparent decrease in the KM value. In contrast, fibrin-dependent enhancement of t-PA activity against low molecular weight peptides is exclusive to sct-PA and is characterized by an increase in the kcat value and, depending on the nature of the substrate, by an increase in kcat and a decrease in KM. Thus, sct-PA activity modulation depends strictly on the correct three-dimensional folding of fibrin and is not mediated by fibrinogen fragment FCB-2 or isolated fibrin chains.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Comparison of fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator (t-PA) and fibrin-dependent enhancement of amidolytic activity of t-PA. 160 92

The rate of activation of plasminogen by tissue-type plasminogen activator (t-PA) is greatly increased by fibrin, but much less by fibrinogen. Fibrin(ogen) fragments such as the fibrin(ogen) cyanogen bromide fragment FCB-2 and FCB-5, and a synthetic peptide with the sequence of fibrinogen A alpha-(148-160), a constituent of FCB-2, also have rate-enhancing properties. In order to find a possibly smaller, still stimulating site within A alpha-(148-160) we synthesized successive linear amino-terminally acylated hexapeptides [i.e. A alpha-(148-153), A alpha-(149-154)'d, .... A alpha-(155-160)] from the sequence A alpha-(148-160). The only hexapeptide within the sequence A alpha-(148-160) capable of enhancing the rate of plasminogen-to-plasmin conversion by t-PA appears to be the amino-terminally acylated peptide comprising the sequence A alpha-(154-159). This peptide enhances the plasminogen activation rate six-fold; half-maximal activation rate is reached at a peptide concentration of 56 microM.
 ...
PMID:The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. 193 32

Intact fibrin monomer, the early fibrin degradation product (X-fragment), late fibrinogen degradation products (fragments D and E), fibrinogen cyanogen bromide fragment FCB-2, and isolated peptide chains of fibrinogen and fibrin were investigated for their ability to replace fibrin in the stimulation of one-chain tissue-type plasminogen activator. They were also investigated for their ability to stimulate plasminogen activation by one-chain tissue-type plasminogen activator, which occurs via ternary complex formation. The stimulatory effect of the different fibrin/ogen products decreased in the order: fibrin X-fragment greater than fibrin monomer greater than CNBr-fragment FCB-2 greater than fibrin alpha-chain. Fibrin beta/gamma-chains and fibrinogen peptide chains were found to be weak stimulators. Fibrinogen fragments D and E have almost no effect. The amidolytic activity of one-chain tissue-type plasminogen activator was stimulated by intact fibrin monomer and somewhat more strongly by fibrin X-fragment. This stimulation by fibrin monomer, which occurred via an increase in the kcat value, was competitively inhibited by isolated fibrin alpha-chain (Ki = 0.12 mumol/l). The results show that the fibrin-mediated stimulation of plasminogen activation occurs when both one-chain tissue-type plasminogen activator and plasminogen are bound to fibrin, and that this process is essentially independent of the conformation of the fibrin molecule. In comparison, the fibrin-dependent stimulation of the amidolytic activity of one-chain tissue-type plasminogen activator is a more complex process, which depends on the correct conformation of the fibrin molecule.
 ...
PMID:Comparison of the effects of fibrinogen and fibrin products and isolated peptide chains on the fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator, and on the fibrin-dependent enhancement of the amidolytic activity of one-chain tissue-type plasminogen activator. 212 81

HTC rat hepatoma cells synthesize and secrete tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1). Incubation with 8-bromo-cAMP increases tPA activity more than 50-fold and, in combination with dexamethasone, causes an additional 4-fold increase. We have investigated the mechanism of the regulation of tPA activity by cyclic nucleotides, both alone and in combination with dexamethasone, by examining the effects of these agents on tPA and PAI-1 mRNA and protein. 8-Bromo-cAMP induces only a 2-fold increase in tPA mRNA and a 5-fold increase in tPA protein which is not sufficient to account for the increase in tPA activity. However, 8-bromo-cAMP causes a 90% decrease in PAI-1 mRNA and a 60-70% decrease in PAI-1 protein, which, taken together with the modest increase in tPA mRNA and protein, can account for the increase in tPA activity. Incubation with 8-bromo-cAMP plus dexamethasone also results in an 80-90% decrease in PAI-1 mRNA, but causes a synergistic 10- to 20-fold increase in tPA mRNA and protein. Regulation of both mRNAs by 8-bromo-cAMP requires concomitant RNA synthesis. Inhibition of protein synthesis by cycloheximide totally blocks the 8-bromo-cAMP-induced decrease in PAI-1 mRNA. Cycloheximide alone causes a 5- to 10-fold increase in tPA mRNA, and no further hormonal effect is observed. Thus, 8-bromo-cAMP increases tPA activity primarily by decreasing PAI-1 mRNA accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells. 215 75

In order to localize the binding site(s) for tissue-type plasminogen activator (t-PA) in the fibrin(ogen) molecule, the following binding assay was developed. Two-chain t-PA was immobilized onto microtitration plates. The t-PA-coated plates were then incubated with fibrinogen and various fibrinogen fragments. The extent of binding was quantified with enzyme-labelled antibodies against fibrin(ogen) and its fragments. Hardly any binding to t-PA was observed with fibrinogen or fragments X, Y and E; a moderate binding was observed with fragments Dcate and DEGTA and a strong binding with the cyanogen bromide fragment FCB-2 (Kd apparent = 140 nM). The binding of fibrinogen and its fragments to immobilized Lys-plasminogen was measured by the same method as a control for the binding assay. Results were in line with literature data: virtually no binding to Lys-plasminogen with fibrinogen or fragments X and Y, a moderate binding with fragments Dcate, DEGTA and E and a strong binding with FCB-2 (Kd apparent = 70 nM). The stimulatory capacity of the various fragments on the Lys-plasminogen activation by t-PA, as studied in a spectrophotometric assay, was found to be absent for fragment E, low for fibrinogen, fragments X, Y, Dcate and DEGTA, and high for FCB-2. It is concluded that a t-PA-binding site resides in the C-terminal globular domains of fibrinogen from which fragments D and FCB-2 originate. The site is hidden in the native fibrinogen molecule and in early fibrinogen degradation products. Binding of both Lys-plasminogen and t-PA appears to be required for a stimulator of the plasminogen activation, as illustrated by fragment E which only binds Lys-plasminogen and has no stimulatory capacity.
 ...
PMID:Binding of tissue-type plasminogen activator to fibrinogen fragments. 312 7

Activation of human plasminogen by human tissue-type plasminogen activator (t-PA) is accelerated in the presence of cyanogen bromide digests of human fibrin(ogen). In the present study a possible species specificity of this phenomenon was investigated. All combinations of the plasminogens, fibrin monomers and cyanogen bromide digests of the fibrinogens of man, pig, rat, cat and monkey (Macaca mulatta), and three t-PA species (man, rat and pig) were studied. No species differences were noted with the fibrin monomers i.e. the activation rate of all five plasminogens increased more than 20-fold in the presence of all five fibrin monomer species, irrespective if man, rat or pig t-PA was used. However, we found that species specificities come to expression when cyanogen bromide digests of the corresponding fibrinogens were used as accelerators. Our results indicate that the plasminogen species and not the source of t-PA or fibrinogen dictates if accelerated activation occurs in the presence of a fibrinogen CNBr digest. The plasminogens can be roughly divided in two groups: --One group, comprising human, monkey and cat plasminogen, which are activated at a higher rate by all three t-PA species in the presence of fibrinogen digest independent on the fibrinogen species from which the digest was prepared. --Another group, comprising pig and rat plasminogen, which is not or only marginally more quickly activated by the 3 t-PA species, irrespective of the fibrinogen species from which the CNBr digest was prepared.
 ...
PMID:Species specificity in the acceleration of tissue-type plasminogen activator-mediated activation of plasminogens, by fibrinogen cyanogen bromide fragments. 404 Jun 60

The activation rate of plasminogen by tissue-type plasminogen activator can be increased by fibrin(ogen) fragments. There is a remarkable difference in the effect of these fragments on the stimulation of 1-glu-plasminogen activation and 442-val-plasminogen (mini-plasminogen) activation. Fibrin monomer as well as plasmic fragments Y, D EGTA and D-dimer have a stimulating effect on both 1-glu-plasminogen and 442-val-plasminogen activation, whereas cyanogen bromide fragment FCB2 stimulates only the activation of 1-glu-plasminogen. Results indicate that two types of sites may be operational in fibrin and fibrin(ogen) fragments Y, D EGTA and D-dimer. One type of site (FCB2-related) interacts probably with plasminogen and may be dependent on the kringle 1-4 region; the other type of site probably interacts either with plasminogen in a non-kringle 1-4 region-dependent manner or with tissue-type plasminogen activator.
 ...
PMID:Differences in effects of fibrin(ogen) fragments on the activation of 1-glu-plasminogen and 442-val-plasminogen by tissue-type plasminogen activator. 622 56

Fibrin, in contrast to fibrinogen, strongly accelerates the plasminogen activation by extrinsic activator (tissue-type plasminogen activator, t-PA). However, when fibrin and fibrinogen are digested with cyanogen bromide, both digests potentiate the t-PA-mediated plasminogen activation equally well. In this report, evidence is presented that this potentiating activity resides in CNBr fragment FCB-2 (= Ho1-DSK) and that a polymeric structure such as fibrin is not a prerequisite for the potentiation.
 ...
PMID:Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. 668 16

Conditions for the fibrinogen fragmentation with 2-pyridyl-or o-nitrophenylsulfenylchloride were proposed. Resulting mixture of fragments is identical to the mixture prepared by the cyanogen bromide treatment and is suitable as supplementary analytical reagent in the determination of the tissue plasminogen activator (TPA) activity with a chromogenic substrate.
 ...
PMID:[Use of arylsulfenylchlorides for cleaving fibrinogen at methionine residues]. 848 35

The intrapulmonary thrombi that form after the cessation of circulation are thought to be one of the major causes of graft function failure. We evaluated the effect of recombinant tissue-type plasminogen activator (rt-PA) in a canine cadaver lung transplant model. Donor dogs were killed by the intravenous administration of pancuronium bromide without heparinization, and left for 2 h at room temperature. The donor lungs were then flushed with low potassium dextran glucose (LPDG) solution, being subjected to a total ischemic time of 3 h. Following left lung transplantation, the contralateral pulmonary artery of the recipient dogs was ligated. In group 1 (n = 6), chloride solution was administered from the main pulmonary artery for 90 min, commencing 15 min prior to reperfusion. In group 2 (n = 6), 2.5 microg/kg per min of rt-PA, and in group 3 (n = 6), 5.0 microg/kg per min of rt-PA, were continuously infused in the same manner as in group 1. Lung function, including arterial blood gases and pulmonary hemodynamics, was measured for 3 h. The side effects of rt-PA were evaluated by measuring the prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, alpha2-plasmin inhibitor (alpha2-PI), plasminogen, and fibrin/fibrinogen degradation product (FDP). All of the animals in the three groups survived throughout the observation period. The group 3 animals had significantly better gas exchange than the group 1 animals, and the pulmonary hemodynamics were significantly better in the group 2 and 3 animals than in the group 1 animals. The FDP levels in the group 2 and 3 animals were significantly higher than those in the group 1 animals, while the PT and APTT were significantly prolonged in the group 3 animals. These findings led us to conclude that rt-PA improves early lung function, particularly pulmonary hemodynamics.
 ...
PMID:The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation. 1048 50


1 2 Next >>